Important New Data on Kevetrin to be Presented at April Meeting
BEVERLY, MA–(Marketwire – March 15, 2010) – Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that the American Association for Cancer Research (AACR) has accepted an abstract of data on Kevetrin for presentation at its 101st Annual Meeting from April 17th to 22nd in Washington, DC. This abstract titled “Novel small molecule has potent anti-tumor activity in drug resistant tumor xenograft models” contains data on Kevetrin that have not previously been made public. The abstract will be presented at a session entitled “Late-Breaking Research: Experimental and Molecular Therapeutics 2,” on April 20.
“This is a significant event for Cellceutix,” said its Chief Scientific Officer, Dr. Krishna Menon. “The AACR is the premier cancer research organization and its annual meeting attracts scientists and pharma executives throughout the world. We are pleased to be able to present our data at the upcoming meeting.”
In animal studies, Kevetrin was found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. More information about these studies is available on the Cellceutix web site at www.cellceutix.com.